Wyndham H Wilson

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma
    Wyndham H Wilson
    Lymphoid Malignancy Branch, National Cancer Institute, Bethesda, MD, USA
    Haematologica 99:1228-35. 2014
  2. pmc A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype
    Wyndham H Wilson
    Metabolism Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Haematologica 97:758-65. 2012
  3. ncbi request reprint Novel disease targets and management approaches for diffuse large B-cell lymphoma
    Wyndham H Wilson
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Leuk Lymphoma 51:1-10. 2010
  4. pmc Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
    Wyndham H Wilson
    National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Lancet Oncol 11:1149-59. 2010
  5. pmc Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers
    Wyndham H Wilson
    Metabolism Branch, National Cancer Institute, Building 10, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Clin Oncol 26:2717-24. 2008
  6. pmc Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies
    Rachel B Salit
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Clin Oncol 30:830-6. 2012
  7. pmc The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma
    Kieron Dunleavy
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 115:3017-24. 2010
  8. pmc Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma
    Kieron Dunleavy
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Blood 113:6069-76. 2009
  9. pmc Low-intensity therapy in adults with Burkitt's lymphoma
    Kieron Dunleavy
    From the Center for Cancer Research, National Cancer Institute, Bethesda, MD
    N Engl J Med 369:1915-25. 2013
  10. ncbi request reprint Rituximab-associated neutropenia
    Kieron Dunleavy
    Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Semin Hematol 47:180-6. 2010

Detail Information

Publications84

  1. pmc Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma
    Wyndham H Wilson
    Lymphoid Malignancy Branch, National Cancer Institute, Bethesda, MD, USA
    Haematologica 99:1228-35. 2014
    ..003) but not with survival. Our results suggest that patients at risk of central nervous system disease should be evaluated by flow cytometry and that intrathecal prophylaxis/therapy is beneficial. ..
  2. pmc A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype
    Wyndham H Wilson
    Metabolism Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Haematologica 97:758-65. 2012
    ..The Cancer and Leukemia Group B conducted a study to determine if these results could be reproduced in a multi-institutional setting...
  3. ncbi request reprint Novel disease targets and management approaches for diffuse large B-cell lymphoma
    Wyndham H Wilson
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Leuk Lymphoma 51:1-10. 2010
    ..As more targeted agents are developed, the timing of administration with other agents in clinical trials will become increasingly important to ensure maximal efficacy while minimizing side effects...
  4. pmc Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
    Wyndham H Wilson
    National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Lancet Oncol 11:1149-59. 2010
    ..We aimed to assess the safety and antitumour activity of navitoclax in patients with lymphoid tumours, and establish the drug's pharmacokinetic and pharmacodynamic profiles...
  5. pmc Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers
    Wyndham H Wilson
    Metabolism Branch, National Cancer Institute, Building 10, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Clin Oncol 26:2717-24. 2008
    ....
  6. pmc Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies
    Rachel B Salit
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Clin Oncol 30:830-6. 2012
    ..To this end, we developed a novel regimen by adding fludarabine to dose-adjusted continuous-infusion etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin plus with or without rituximab (DA-EPOCH-F/R)...
  7. pmc The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma
    Kieron Dunleavy
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 115:3017-24. 2010
    ..However, new therapeutic advances are needed for non-GCB DLBCL, which remains the important cause of lymphoma-specific death. This trial was registered at www.clinicaltrials.gov as NCT000019253...
  8. pmc Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma
    Kieron Dunleavy
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Blood 113:6069-76. 2009
    ..This trial is registered with http://www.ClinicalTrials.gov under identifier NCT00057902...
  9. pmc Low-intensity therapy in adults with Burkitt's lymphoma
    Kieron Dunleavy
    From the Center for Cancer Research, National Cancer Institute, Bethesda, MD
    N Engl J Med 369:1915-25. 2013
    ..Current treatments are less effective and have more severe side effects in adults and patients with immunodeficiency than in children...
  10. ncbi request reprint Rituximab-associated neutropenia
    Kieron Dunleavy
    Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Semin Hematol 47:180-6. 2010
    ..Late-onset neutropenia is intriguing biologically and while its pathogenesis and mechanism are not completely understood, many interesting hypotheses have been proposed to explain its occurrence...
  11. ncbi request reprint Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology
    Richard F Little
    Center for Cancer Research CCR, National Cancer Institute NCI, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 101:4653-9. 2003
    ..These results suggest that tumor pathogenesis is responsible for the improved outcome of ARLs in the era of HAART...
  12. ncbi request reprint Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy
    Wyndham H Wilson
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Blood 99:2685-93. 2002
    ..Dose-adjusted EPOCH may produce more cell kill than CHOP-based regimens. Dynamic dose adjustment may overcome inadequate drug concentrations, particularly in younger patients, and compensate for increased drug clearance over time...
  13. ncbi request reprint Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma
    John E Janik
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 104:3355-7. 2004
    ..Serum sIL-2R levels were elevated in both patients with recurrent disease...
  14. pmc Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
    James N Kochenderfer
    Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Blood 116:4099-102. 2010
    ..Adoptive transfer of anti-CD19-CAR-expressing T cells is a promising new approach for treating B-cell malignancies. This study is registered at www.clinicaltrials.gov as #NCT00924326...
  15. ncbi request reprint Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
    Sandeep S Dave
    National Cancer Institute, NIH, Bethesda, MD 20892, USA
    N Engl J Med 351:2159-69. 2004
    ..We used gene-expression profiles of tumor-biopsy specimens obtained at diagnosis to develop a molecular predictor of the length of survival...
  16. ncbi request reprint Gray zone lymphoma: better treated like hodgkin lymphoma or mediastinal large B-cell lymphoma?
    Kieron Dunleavy
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, Rockville Pk, Bethesda, MD 20892, USA
    Curr Hematol Malig Rep 7:241-7. 2012
    ....
  17. pmc Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma
    Marc A Weniger
    Hematology Branch, NHLBI, NIH, Building 10, CRC 3 5140, 10 Center Drive, Bethesda, 20892 MD, USA
    Clin Cancer Res 17:5101-12. 2011
    ..Up to 50% of patients with relapsed mantle cell lymphoma (MCL) respond to bortezomib. We used gene expression profiling to investigate the connection between proteasome inhibition, cellular response, and clinical efficacy...
  18. ncbi request reprint The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
    Andreas Rosenwald
    The Lymphoma Leukemia Molecular Profiling Project, National Cancer Institute NIH, Bethesda, MD, USA
    Cancer Cell 3:185-97. 2003
    ..We propose a quantitative model of the aberrant cell cycle regulation in MCL that provides a rationale for the design of cell cycle inhibitor therapy in this malignancy...
  19. ncbi request reprint High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology
    Upendra Hegde
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health Bethesda, MD 20892 1868, USA
    Blood 105:496-502. 2005
    ..Patients at risk for CNS spread should undergo staging CSF evaluation by flow cytometry...
  20. doi request reprint Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma
    Kieron Dunleavy
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 368:1408-16. 2013
    ..We aimed to develop a strategy that improves the rate of cure and obviates the need for radiotherapy...
  21. pmc Improved ZAP-70 assay using two clones, multiple methods of analysis and clinical correlation
    Heba A Degheidy
    Division of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Cytometry B Clin Cytom 80:309-17. 2011
    ..In a companion methodological study, we compared two anti-ZAP-70 clones (1E7.2 AF 488 and SBZAP PE) and four selected methods of analysis. Clinical correlations are required for validation...
  22. pmc Methodological comparison of two anti-ZAP-70 antibodies
    Heba A Degheidy
    Center for Biologics Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20892, USA
    Cytometry B Clin Cytom 80:300-8. 2011
    ..ZAP-70 expression is a stage independent prognostic marker in CLL. However, interlaboratory variation is large, and there is neither a consensus nor a regulatory approved methodology...
  23. pmc Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia
    Clifton C Mo
    Hematology Branch, NHLBI, NIH, Bethesda, MD, USA
    Haematologica 98:1259-63. 2013
    ..More frequent dosing of rituximab may be required to prevent autoimmune complications in at-risk patients (clinicaltrials.gov identifier:00001586). ..
  24. pmc Bcl-2 level as a biomarker for 13q14 deletion in CLL
    Heba A Degheidy
    Center for Biologics Evaluation and Research, FDA, Bethesda, MD, USA
    Cytometry B Clin Cytom 84:237-47. 2013
    ..Therefore, Bcl-2 expression was examined more closely to determine whether it would predict 13q14 deletion status...
  25. ncbi request reprint Molecular diagnosis of Burkitt's lymphoma
    Sandeep S Dave
    National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    N Engl J Med 354:2431-42. 2006
    ..We examined whether gene-expression profiling could reliably distinguish Burkitt's lymphoma from diffuse large-B-cell lymphoma...
  26. pmc B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis
    Kieron Dunleavy
    Experimental Transplantation and Immunology Branch, CCR, NCI, Bldg 10, Rm 12 N 226, Bethesda, MD, 20892 1868, USA
    Blood 106:795-802. 2005
    ..These findings illustrate the dual role of SDF-1 in human B-cell and granulocyte homeostasis...
  27. pmc Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma
    Andreas Rosenwald
    Metabolism Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA
    J Exp Med 198:851-62. 2003
    ..The molecular diagnosis of PMBL should significantly aid in the development of therapies tailored to this clinically and pathogenetically distinctive subgroup of DLBCL...
  28. pmc Targeting malignant B cells with an immunotoxin against ROR1
    Sivasubramanian Baskar
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    MAbs 4:349-61. 2012
    ..Our data suggest that ROR1-immunotoxins such as BT-1 could serve as targeted therapeutic agents for ROR1-expressing B cell malignancies and other cancers...
  29. ncbi request reprint The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R
    Wyndham H Wilson
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Semin Oncol 29:41-7. 2002
    ..These results suggest that rituximab may modulate the sensitivity of B-cell lymphomas to chemotherapy...
  30. pmc Nodal involvement by cutaneous CD30-positive T-cell lymphoma mimicking classical Hodgkin lymphoma
    Franziska C Eberle
    Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Am J Surg Pathol 36:716-25. 2012
    ..We show that cHL is less often associated with MF and primary cutaneous CD30-T-LPD than previously thought and that the coexpression of CD30 and CD15 in these TCLs may lead to a mistaken diagnosis of cHL...
  31. pmc B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
    James N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute NCI, Bethesda, MD 20892, USA
    Blood 119:2709-20. 2012
    ....
  32. ncbi request reprint Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-hodgkin lymphoma
    Robert M Dean
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 1203, USA
    Biol Blood Marrow Transplant 11:593-9. 2005
    ....
  33. pmc The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia
    Yair Herishanu
    National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 117:563-74. 2011
    ..These data identify the disruption of tumor microenvironment interactions and the inhibition of BCR signaling as promising therapeutic strategies in CLL. This study is registered at http://clinicaltrials.gov as NCT00019370...
  34. pmc Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia
    Robert J Kreitman
    Laboratory of Molecular Biology, Laboratory of Clinical Pathology, and Medicine Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    J Clin Oncol 27:2983-90. 2009
    ..To conduct a phase II trial in chemoresistant hairy cell leukemia (HCL) with BL22, a recombinant anti-CD22 immunotoxin which showed phase I activity in HCL...
  35. ncbi request reprint Focus on lymphomas
    Louis M Staudt
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer Cell 2:363-6. 2002
  36. ncbi request reprint Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response
    Andreas Rosenwald
    Metabolism Branch, Center for Cancer Research, National Cancer Institute NIH, Bldg 10, Rm 4N114, Bethesda, MD 20892, USA
    Blood 104:1428-34. 2004
    ..These considerations suggest that fludarabine treatment should be given in strict accordance to the current National Cancer Institute (NCI) guidelines that have established criteria of disease activity that warrant treatment...
  37. doi request reprint Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations
    Franziska C Eberle
    Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Mod Pathol 24:1586-97. 2011
    ....
  38. pmc Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation
    Patricia Perez-Galan
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 117:542-52. 2011
    ..Expression of CD38 and IRF4 could serve as markers of bortezomib resistance in MCL. This study has been registered at http://clinicaltrials.gov as NCT00131976...
  39. pmc Coexisting and clonally identical classic hodgkin lymphoma and nodular lymphocyte predominant hodgkin lymphoma
    Joo Y Song
    Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Am J Surg Pathol 35:767-72. 2011
    ..NLPHL and cHL are 2 distinct diseases and are almost never seen concurrently. We present a case in which polymerase chain reaction analysis indicated that the tumor cells of these 2 distinct entities were clonally identical...
  40. pmc Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival
    Adrian Wiestner
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Blood 109:4599-606. 2007
    ..We conclude that alterations of CCND1 3'UTR structure can significantly increase its oncogenic effect and worsen the clinical course of MCL patients...
  41. ncbi request reprint Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma
    Sattva S Neelapu
    Experimental and Transplantation Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, Maryland 20892, USA
    Nat Med 11:986-91. 2005
    ..Based on these results, it is justifiable to administer vaccines in the setting of B-cell depletion; however, vaccine boosts after B-cell recovery may be necessary for optimal humoral responses...
  42. doi request reprint Phase I trial of 7-hydroxystaurosporine and fludararbine phosphate: in vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia
    Gerald E Marti
    Laboratory of Stem Cell Biology, Cellular and Tissue Therapy Branch, Division of Cell and Gene Therapies, Office of Cellular, Tissues and Gene Therapies, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Leuk Lymphoma 52:2284-92. 2011
    ..UCN-01 does not increase FAMP toxicity. Transient lymphocytosis followed by apoptosis occurs with UCN-01. Mobilization from tissue reservoirs may play a role in the induction of cell death in malignant lymphocytes...
  43. doi request reprint Primary mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do?
    Cliona Grant
    Metabolism Branch, National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892, USA
    Curr Hematol Malig Rep 6:157-63. 2011
    ..Historical data indicate that they have done poorly with traditional approaches developed for the treatment of either CHL or diffuse large B-cell lymphoma...
  44. pmc Circulating serum free light chains as predictive markers of AIDS-related lymphoma
    Ola Landgren
    National Cancer Institute, National Institutes of Health, Center for Cancer Research, Medical Oncology Branch, 9000 Rockville Pike, Bldg 10 Room 13N240, Bethesda, MD, 20892, USA
    J Clin Oncol 28:773-9. 2010
    ..CONCLUSION Elevated FLCs may represent sensitive markers of polyclonal B-cell activation and dysfunction and could be useful for identifying HIV-infected persons at increased NHL risk...
  45. pmc EBV-associated lymphomas in adults
    Mark Roschewski
    Walter Reed National Military Medical Center, Bethesda, MD 20814, USA
    Best Pract Res Clin Haematol 25:75-89. 2012
    ....
  46. ncbi request reprint Lymphomatoid granulomatosis and other Epstein-Barr virus associated lymphoproliferative processes
    Kieron Dunleavy
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Curr Hematol Malig Rep 7:208-15. 2012
    ....
  47. pmc New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies
    Kieron Dunleavy
    Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 1868, USA
    Clin Cancer Res 16:5608-17. 2010
    ..In this respect, there is a need for new approaches in these diseases, and this review focuses on and explores recent experience with novel therapies in PTCL...
  48. ncbi request reprint Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas
    Michael R Bishop
    Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Biol Blood Marrow Transplant 9:162-9. 2003
    ....
  49. doi request reprint Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia
    Robert J Kreitman
    Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Leuk Lymphoma 52:82-6. 2011
    ..In separate randomized trials, rituximab is undergoing phase II testing with cladribine for early HCL and with bendamustine or pentostatin for multiply relapsed HCL...
  50. ncbi request reprint The BCL-2 biomarker in the era of molecular diagnosis of diffuse large B-cell lymphoma
    Kieron Dunleavy
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Leuk Lymphoma 48:1061-3. 2007
  51. pmc High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients
    Brad Moriyama
    National Institutes of Health Clinical Center Pharmacy Department, Bethesda, MD 20892, USA
    Ann Pharmacother 44:929-35. 2010
    ..To report a case series of high-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections...
  52. ncbi request reprint A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy
    John C Morris
    Metabolism Branch, Laboratory of Pathology, Department of Laboratory Medicine, National Eye Institute, Bethesda, MD 20892 1457, USA
    Clin Cancer Res 13:958-64. 2007
    ..The primary end point was to determine drug toxicity. Tumor response, tumor-specific CD8+ T-cell immune responses, and modulation of CD4+ CD25+ FoxP3+ regulatory T-cell (Treg) numbers were secondary end points...
  53. pmc B-cell lymphoma in a patient with complete interferon gamma receptor 1 deficiency
    Hannelore I Bax
    Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    J Clin Immunol 33:1062-6. 2013
    ..As more of these patients survive their early infections, cancer awareness and tumor surveillance may need to become a more routine part of management. ..
  54. pmc How I treat HIV-associated lymphoma
    Kieron Dunleavy
    Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Blood 119:3245-55. 2012
    ..Future clinical trials need to investigate novel targeted agents alone and in combination with chemotherapy...
  55. pmc Nodal and extranodal plasmacytomas expressing immunoglobulin a: an indolent lymphoproliferative disorder with a low risk of clinical progression
    Haipeng Shao
    Laboratory of Pathology and the Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Am J Surg Pathol 34:1425-35. 2010
    ..Our results suggest that IgA plasmacytomas may represent a distinct form of extramedullary plasmacytoma characterized by younger age at presentation, frequent lymph node involvement, and low risk of progression to plasma cell myeloma...
  56. pmc Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor
    James N Kochenderfer
    Surgery Branch of the National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 32:689-702. 2009
    ....
  57. ncbi request reprint Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies
    Robert J Kreitman
    Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bldg 5124b, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Clin Oncol 23:6719-29. 2005
    ..To conduct a phase I trial of recombinant immunotoxin BL22, an anti-CD22 Fv fragment fused to truncated Pseudomonas exotoxin...
  58. ncbi request reprint A Phase I/II Study of a Hybrid Schedule of Flavopiridol in Relapsed/Refractory Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma
    Kieron Dunleavy
    National Cancer Institute, Bethesda, MD
    Clin Lymphoma Myeloma Leuk 10:E27. 2010
    ..TLS occurred infrequently and was reversible. DLTs were TLS and gastrointestinal toxicity. Accrual continues. Analysis of cell cycle and transcriptional CDK targets is ongoing...
  59. doi request reprint Novel agents for B-cell non-Hodgkin lymphoma: science and the promise
    Kevin Tay
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Centre Drive, Bethesda, MD 20892 1203, USA
    Blood Rev 24:69-82. 2010
    ..The purpose of this review is to focus on these novel agents and the various treatment approaches that are currently being evaluated in non-Hodgkin lymphoma...
  60. pmc Combined normal donor and CLL: Single tube ZAP-70 analysis
    Heba A Degheidy
    Center for Biologics Evaluation and Research, FDA, Bethesda, Maryland, USA
    Cytometry B Clin Cytom 82:67-77. 2012
    ..Based on our previous studies, we have developed a combined one-tube technology with multiple internal controls to optimize ZAP-70 assessment...
  61. ncbi request reprint Acquired immunodeficiency syndrome-related malignancies in the era of highly active antiretroviral therapy
    Wendy B Bernstein
    HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1868, USA
    Int J Hematol 84:3-11. 2006
    ..Strategies for prevention, screening, and therapy remain important areas of research in this developing field...
  62. pmc Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia
    Robert J Kreitman
    National Cancer Institute, National Institutesof Health, Bethesda, USA
    J Clin Oncol 30:1822-8. 2012
    ..To conduct a phase I dose-escalation trial assessing safety and response of recombinant immunotoxin moxetumomab pasudotox (CAT-8015, HA22) in chemotherapy-resistant hairy cell leukemia (HCL)...
  63. ncbi request reprint Primary intraocular lymphoma: current and future perspectives
    Kieron Dunleavy
    Center for Cancer Research, National Cancer Institute, Building 10, 9000 Rockville Pike, Bethesda, MD, USA
    Leuk Lymphoma 47:1726-7. 2006
  64. pmc Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
    R Eric Davis
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 463:88-92. 2010
    ..These findings establish chronic active BCR signalling as a new pathogenetic mechanism in ABC DLBCL, suggesting several therapeutic strategies...
  65. doi request reprint Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia
    Sivasubramanian Baskar
    Experimental Transplantation and Immunology Branch and Metabolism Branch, Center for Cancer Research, National Cancer Institute, and Hematology Branch, National Heart, Lung and Blood Institute, NIH, Bethesda, MD 20892 1203, USA
    Clin Cancer Res 14:396-404. 2008
    ..To assess the suitability of ROR1 as a cell surface antigen for targeted therapy of B-CLL, we carried out a comprehensive analysis of ROR1 protein expression...
  66. ncbi request reprint Lymphomatoid granulomatosis: abnormalities of the brain at MR imaging
    Athos D Patsalides
    Department of Diagnostic Radiology, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bldg 10, Room 1C660, 9000 Rockville Pike, Bethesda, MD 20892 1182, USA
    Radiology 237:265-73. 2005
    ..To retrospectively evaluate the magnetic resonance (MR) imaging features of lymphomatoid granulomatosis in the brain...
  67. ncbi request reprint ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile
    Adrian Wiestner
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
    Blood 101:4944-51. 2003
    ..We developed reverse transcriptase-polymerase chain reaction and immunohistochemical assays for ZAP-70 expression that can be applied clinically and would yield important prognostic information for patients with CLL...
  68. ncbi request reprint Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia
    Upendra P Hegde
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 100:2260-2. 2002
    ..These results suggest rituximab can rapidly reverse refractory fludarabine-associated ITP...
  69. ncbi request reprint The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
    Andreas Rosenwald
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 346:1937-47. 2002
    ..The survival of patients with diffuse large-B-cell lymphoma after chemotherapy is influenced by molecular features of the tumors. We used the gene-expression profiles of these lymphomas to develop a molecular predictor of survival...
  70. ncbi request reprint Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications
    Kieron Dunleavy
    Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Curr Opin Hematol 14:348-53. 2007
    ..The prognosis with traditional chemotherapy has been poor, but improved understanding of the disease's pathobiology has led to several promising novel therapeutic strategies...
  71. doi request reprint Mycosis fungoides and S├ęzary syndrome
    Sam T Hwang
    Dermatology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, USA
    Lancet 371:945-57. 2008
    ....
  72. pmc International Central Nervous System and Ocular Lymphoma Workshop: recommendations for the future
    Robert B Nussenblatt
    Laboratory of Immunology, National Eye Institute, NIH, 10 Center Drive, Building 10, Room 10S219, Bethesda, MD, 20892, USA
    Ocul Immunol Inflamm 14:139-44. 2006
    ..To bring together multidisciplinary experts to discuss primary central nervous system lymphoma (PCNSL) and primary intraocular lymphoma (PIOL)...
  73. ncbi request reprint The pharmacokinetics of rituximab following an intravitreal injection
    Hyuncheol Kim
    National Eye Institute, National Institutes of Health, Bethesda, MD 20892 1863, USA
    Exp Eye Res 82:760-6. 2006
    ....
  74. pmc Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma
    Franziska C Eberle
    Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Haematologica 96:558-66. 2011
    ..Epigenetic changes have been implicated in the loss of the B-cell program in classical Hodgkin's lymphoma, and might provide a basis for the immunophenotypic alterations seen in mediastinal gray zone lymphoma...
  75. pmc A novel role for IL-22R1 as a driver of inflammation
    Ram Savan
    Cancer and Inflammation Program, Center for Cancer Research, Frederick, MD, USA
    Blood 117:575-84. 2011
    ..This study documents a previously unknown role of IL-22R1 in inflammation and identifies the involvement of IL-22R1/IL-22 in ALK(+)ALCL...
  76. ncbi request reprint The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma
    Kieron Dunleavy
    National Cancer Institute, Bethesda, MD 20892, USA
    Leuk Lymphoma 51:28-33. 2010
    ..Current limitations of the technique will be summarized, and innovative uses of PET in grading, staging, and surveying lymphomas will be briefly explored...
  77. ncbi request reprint Drug resistance in diffuse large B-cell lymphoma
    Wyndham H Wilson
    Center for Cancer Treatment, National Cancer Institute, Bethesda, MD
    Semin Hematol 43:230-9. 2006
    ..However, the complexity of drug resistance requires that future clinical trials incorporate molecular translational endpoints to help identify the biologic basis of treatment failure...
  78. pmc Cardiac involvement with lymphoma: a review of the literature
    Deirdre O'Mahony
    Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Clin Lymphoma Myeloma 8:249-52. 2008
    ..We present 2 cases and a review of the literature...
  79. ncbi request reprint Non-Hodgkin's lymphoma in Job's syndrome: a case report and literature review
    Gregory D Leonard
    National Cancer Institute, Bethesda, Maryland 20892, USA
    Leuk Lymphoma 45:2521-5. 2004
    ..With appropriate chemotherapy and hematological support, lymphoma associated with Job's syndrome can achieve complete remission...
  80. pmc Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia
    Georg Aue
    Hematology Branch, National Heart, Lung, and Blood Institute NIH, 10 Center Drive, Bethesda, MD 20892 1202, USA
    Haematologica 94:1266-73. 2009
    ..We conducted this study to investigate the mechanism of action of lenalidomide and the basis for its unique toxicities in chronic lymphocytic leukemia...
  81. ncbi request reprint Transfusion medicine illustrated. Hemophagocytosis and coagulopathy associated with cutaneous gamma-delta T-cell lymphoma
    W Tait Stevens
    Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, Maryland 20892, USA
    Transfusion 44:1679. 2004
  82. ncbi request reprint Extraoular muscle palsies in subcutaneous panniculitis-like T-cell lymphoma
    Gregory D Leonard
    Medical Oncology Clinical Research Unit, National Cancer Institute, Bethesda, MD, USA
    J Clin Oncol 21:2993-5. 2003
  83. pmc Radiofrequency ablation of lymphoma
    Deepak Sudheendra
    Department of Radiology, National Institutes of Health, Bldg 10, Rm 1C 660, Bethesda, MD 20892, USA
    Blood 107:1624-6. 2006
    ..RF ablation may be clinically beneficial and should be considered for the treatment of local lymphoma that is refractory or not amenable to standard approaches...
  84. ncbi request reprint Angioimmunoblastic T-cell lymphoma: immune modulation as a therapeutic strategy
    Kieron Dunleavy
    Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Leuk Lymphoma 48:449-51. 2007